Skip to main content
2024 DC-CSEM Conference Main banner
On-Demand

Accredited Symposium

AS2403 - Beyond Weight-Centric Outcomes: Collaborative Approaches to T2DM Management

Friday, November 22, 2024
07:15 - 08:15 AT Time
Location: Ballroom B3

    Presenter(s)

  • Lori Berard, n/a (she/her/hers)

    Nurse Consultant
    Independent
    Winnipeg, Manitoba, Canada

    Disclosure(s): Abbott Diabetes: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Speaker/Honoraria (Ongoing); Dexcom Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Speaker/Honoraria (Ongoing); EMBECTA: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); MontMed: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk A/S: Consultant (Ongoing)

  • Jennifer Brown, MSc RD CBE (she/her/hers)

    Registered Dietitian
    The Ottawa Hospital Bariatric Centre of Excellence
    Ottawa, Ontario, Canada

    Disclosure(s): AAD Perspective Inc: Consultant (Terminated, August 31, 2023); Bausch Health: Speaker/Honoraria (Terminated, July 31, 2022); Canadian Collaborative Research Network: Speaker/Honoraria (Terminated, June 5, 2024); CME at Sea: Speaker/Honoraria (Terminated, January 3, 2023); Dietitians of Canada: Committee/Planning Member (Ongoing), Speaker/Honoraria (Ongoing); Haldimand Family Health Team: Speaker/Honoraria (Terminated, March 29, 2023); Jennifer Brown Consulting: Employment (Ongoing); Minogue Medical Inc: Independent Contractor (Ongoing); Novo Nordisk Canada: Consultant (Ongoing); Obesity Canada: Advisory Board (Ongoing), Committee/Planning Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Obesity Matters: Speaker/Honoraria (Terminated, June 2, 2023); Palliser Primary Care Network: Speaker/Honoraria (Terminated, November 18, 2022); Paravita: Consultant (Terminated, December 31, 2023); The Ottawa Hospital: Employment (Ongoing); Vincci Tsui RD: Consultant (Terminated, May 4, 2023)

  • Anne-Marie Carreau, MD, MSc (she/her/hers)

    Assistant Professor
    Centre de recherche du CHU de Québec-Université Laval
    Université Laval
    Quebec, Quebec, Canada

    Disclosure(s): Bausch Health: Consultant (Terminated, April 1, 2024)

  • MV

    MICHAEL VALLIS, PhD (he/him/his)

    Associate Professor, Family Medicine
    Dalhousie University
    Dalhousie University
    Halifax, Nova Scotia, Canada

    Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); AbbVie: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Bausch Health: Advisory Board (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); E Lilly: Consultant (Ongoing), Speaker/Honoraria (Ongoing); novo nordisk: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Roche: Consultant (Ongoing), Speaker/Honoraria (Ongoing)

    • Moderator(s)

  • AA

    AMEL ARNAOUT, MD, FRCPC (she/her/hers)

    Endocrinologist
    The Ottawa Hospital
    University of Ottawa
    Ottawa, Ontario, Canada

    Disclosure information not submitted.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism.
This accredited symposium was co-developed with the Canadian Society of Endocrinology and Metabolism and Eli Lilly and was planned to achieve scientific integrity, objectivity and balance.

Learning Objectives:

  • Implement a holistic, patient-centred approach to T2DM management that considers the impact of dysfunctional adiposity or adiposopathy on health outcomes and the role of medications in improving cardiometabolic health.
  • Evaluate strategies to address patient concerns, weight stigma, and expectations regarding the use of T2DM medications, including GLP-1 receptor agonists and GIP/GLP-1 receptor agonists.
  • Develop personalized T2DM treatment plans that integrate pharmacological and lifestyle interventions based on individual patient needs and preferences
  • Apply strategies to effectively manage treatment-related challenges, such as side effects and nutrition concerns, and provide long-term support in T2DM care